c-CBL can reverse tamoxifen resistance in HER2-overexpressed breast cancer cells by inhibiting the formation of ER-c-Src-HER2 complex (Li W. et al., 2018; Huang et al., 2020). Here, ERBB2 is linked to breast carcinoma.